National Institute on Drug Abuse; Notice of Closed Meeting, 70511-70512 [2021-26819]
Download as PDF
70511
Federal Register / Vol. 86, No. 235 / Friday, December 10, 2021 / Notices
OMB approval for a new father Generic
Clearance.
In compliance with the
requirement of the Paperwork
Reduction Act of 1995, the Office of the
Secretary (OS), Department of Health
and Human Services, is publishing the
following summary of a proposed
collection for public comment.
DATES: Comments on the ICR must be
received on or before January 10, 2022.
ADDRESSES: Submit your comments to
OIRA_submission@omb.eop.gov or via
facsimile to (202) 395–5806.
FOR FURTHER INFORMATION CONTACT:
Sherrette Funn, Sherrette.Funn@hhs.gov
or (202) 795–7714. When requesting
information, please include the
document identifier 0990-New-30D and
project title for reference.
SUPPLEMENTARY INFORMATION: Interested
persons are invited to send comments
regarding this burden estimate or any
other aspect of this collection of
information, including any of the
following subjects: (1) The necessity and
utility of the proposed information
collection for the proper performance of
the agency’s functions; (2) the accuracy
of the estimated burden; (3) ways to
enhance the quality, utility, and clarity
of the information to be collected; and
(4) the use of automated collection
techniques or other forms of information
technology to minimize the information
collection burden.
Title of the Collection: The National
Hypertension Control Initiative.
Type of Collection: Father Generic.
SUMMARY:
access to blood pressure screenings, and
(iii) connection to health centers to
encourage proper treatment and
management of hypertension of
screened individuals. This initiative
serves to increase the number of adult
patients with controlled hypertension
and reduce the potential risk of COVIDrelated health outcomes.
AHA aims to conduct an evaluation to
assess the feasibility of the
implementation of each of the three
NHCI strategies. The findings of this
evaluation will inform the improvement
and tailoring of AHA’s communication
approaches about the importance of and
techniques for improving blood pressure
control, including the benefits of
accurately measuring, rapidly acting,
and having a patient-focused approach
to blood pressure control.
OMB No.: 0990–NEW—within OS/
Office of Minority and Health.
Abstract: As part of the federal
response to COVID–19, the U.S.
Department of Health and Human
Services (HHS) has funded a new
initiative involving two cooperative
agreements with the American Heart
Association (AHA) to improve COVID–
19-related health outcomes by
addressing hypertension (high blood
pressure) among racial and ethnic
minority populations.
The $32 million project from the HHS
Office of Minority Health (OMH) and
the Health Resources and Services
Administration (HRSA) Bureau of
Primary Health Care will support the
implementation of the National
Hypertension Control Initiative (NHCI),
a national initiative to improve blood
pressure control among the most at-risk
populations, including racial and ethnic
minorities.
The NHCI will support 350
participating HRSA-funded health
centers by providing patient and
provider education and training for
effective hypertension control as well as
integration of remote blood pressure
monitoring technology into the
treatment of hypertension for patients
served by participating health centers.
The project will also utilize the
American Heart Association’s targeted
media campaigns and existing
partnerships with community-based
organizations (CBOs) to help reach
Black, Latino, and other impacted
communities with (i) culturally and
linguistically appropriate messages, (ii)
Methodology
The evaluation of the NHCI project
will use a mixed methods design,
integrating both quantitative and
qualitative data collection and analyses.
Three main goals of data collection will
be to: (1) Track and monitor systems
change implementation process
information from Community Health
Centers (CHCs) on a quarterly basis, (2)
assess the capacity of NHCI partners to
implement the NHCI project, their
needs, the strengths and weaknesses of
the systems change approach, and the
feasibility of the implementation of the
NHCI in their organizations and
communities, and (3) assess the reach
and success of NHCI project strategies
implemented by partners.
ESTIMATED ANNUALIZED BURDEN TABLE
Number of
respondents
jspears on DSK121TN23PROD with NOTICES1
Type of respondent
Number
responses per
respondent
Average
burden per
response
(in hours)
Total
burden hours
Community and Social Service Occupations (CBO quarterly data entry into
MERD) ..........................................................................................................
Consumers (ETS health lesson learning questionnaires) ...............................
Health care professionals (quarterly data entry in MERD) .............................
Health care professionals (annual focus group) ..............................................
Community and Social Service Occupations (annual focus group) ................
53
63,600
350
16
16
4
1
4
1
1
30/60
10/60
1.5
1.5
1.5
106
10,600
2,100
24
24
Total ..........................................................................................................
64,035
........................
........................
12,854
Sherrette A. Funn,
Paperwork Reduction Act Reports Clearance
Officer, Office of the Secretary.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2021–26805 Filed 12–9–21; 8:45 am]
National Institutes of Health
BILLING CODE 4150–29–P
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
VerDate Sep<11>2014
17:03 Dec 09, 2021
Jkt 256001
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
E:\FR\FM\10DEN1.SGM
10DEN1
70512
Federal Register / Vol. 86, No. 235 / Friday, December 10, 2021 / Notices
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Mechanistic Studies on the Impact of Social
Inequality on the Substance Use Trajectory.
Date: February 3, 2022.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Rebekah Feng, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute on Drug Abuse,
NIH, 3WFN 09C49, MSC 6021, 301 North
Stonestreet Avenue, Rockville, MD 20892,
(301) 827–7245, rebekah.feng@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: December 7, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–26819 Filed 12–9–21; 8:45 am]
Date: January 6, 2022.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F37,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Scott Jakes, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3F37, Rockville, MD
20852, (240) 669–5931, jakesse@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: December 7, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–26820 Filed 12–9–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
jspears on DSK121TN23PROD with NOTICES1
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Small Business Innovation
Research (SBIR) Phase II Program Contract
Solicitation (PHS 2020–1) Topic 086
Development of rapid fungal diagnostics for
select endemic dimorphic fungi (N01).
VerDate Sep<11>2014
17:03 Dec 09, 2021
Jkt 256001
Dated: December 7, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–26818 Filed 12–9–21; 8:45 am]
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
9529, (301) 496–9223, mirahamed.hossain@
nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; NINDS Neuroscience
Development for Advancing the Careers of a
Diverse Research Workforce (R25).
Date: January 11, 2022.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: DeAnna Lynn Adkins,
Ph.D., Scientific Review Officer, Scientific
Review Branch, NINDS/NIH/DHHS,
Neuroscience Center, 6001 Executive Blvd.,
Suite 3208, MSC 9529, Bethesda, MD 20892–
9529, 301–496–9223, deanna.adkins@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; NINDS Small Vessel VCID
Biomarkers Validation Consortium
Coordinating Center (U24) Review Meeting.
Date: January 6, 2022.
Time: 11:00 a.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Mir Ahamed Hossain,
Ph.D., Scientific Review Officer, Scientific
Review Branch, NINDS/NIH/DHHS,
Neuroscience Center, 6001 Executive Blvd.,
Suite 3208, MSC 9529, Bethesda, MD 20892–
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
[Docket No. DHS–2021–0051]
Identifying Recommendations To
Support the Work of the Interagency
Task Force on the Reunification of
Families
Department of Homeland
Security.
ACTION: Request for public input.
AGENCY:
The Department of Homeland
Security (DHS), on behalf of the
Interagency Task Force on the
Reunification of Families (Task Force),
is seeking comments from the public on
recommendations for ways to minimize
the separation of migrant parents and
legal guardians and children entering
the United States, consistent with the
law. This input will help in the drafting
of a report required by the Executive
order titled ‘‘Establishment of
Interagency Task Force on the
Reunification of Families.’’
DATES: Comments must be received on
or before January 10, 2022.
ADDRESSES: You may submit comments,
identified by docket number DHS–
2021–0051, through the Federal
eRulemaking Portal: https://
www.regulations.gov. Comments
SUMMARY:
E:\FR\FM\10DEN1.SGM
10DEN1
Agencies
[Federal Register Volume 86, Number 235 (Friday, December 10, 2021)]
[Notices]
[Pages 70511-70512]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-26819]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning
[[Page 70512]]
individuals associated with the grant applications, the disclosure of
which would constitute a clearly unwarranted invasion of personal
privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Mechanistic Studies on the Impact of Social
Inequality on the Substance Use Trajectory.
Date: February 3, 2022.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Rebekah Feng, Ph.D., Scientific Review Officer,
Scientific Review Branch, National Institute on Drug Abuse, NIH,
3WFN 09C49, MSC 6021, 301 North Stonestreet Avenue, Rockville, MD
20892, (301) 827-7245, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: December 7, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-26819 Filed 12-9-21; 8:45 am]
BILLING CODE 4140-01-P